KEGG   PATHWAY: hsa04640Help
Entry
hsa04640                    Pathway                                

Name
Hematopoietic cell lineage - Homo sapiens (human)
Description
Blood-cell development progresses from a hematopoietic stem cell (HSC), which can undergo either self-renewal or differentiation into a multilineage committed progenitor cell: a common lymphoid progenitor (CLP) or a common myeloid progenitor (CMP). A CLP gives rise to the lymphoid lineage of white blood cells or leukocytes-the natural killer (NK) cells and the T and B lymphocytes. A CMP gives rise to the myeloid lineage, which comprises the rest of the leukocytes, the erythrocytes (red blood cells), and the megakaryocytes that produce platelets important in blood clotting. Cells undergoing these differentiation process express a stage- and lineage-specific set of surface markers. Therefore cellular stages are identified by the specific expression patterns of these genes.
Class
Organismal Systems; Immune system
BRITE hierarchy
Pathway map
Hematopoietic cell lineage
hsa04640

All organismsOrtholog table
Disease
H00219  
Hemophilia
H00224  
Bernard-Soulier syndrome
Drug
D01441  
Imatinib mesilate (JAN)
D02596  
Tocilizumab (genetical recombination) (JAN)
D02994  
Rituximab (genetical recombination) (JAN)
D03058  
Basiliximab (genetical recombination) (JAN)
D03231  
Epoetin alfa (genetical recombination) (JP16)
D03232  
Epoetin beta (genetical recombination) (JP16)
D03259  
Gemtuzumab ozogamicin (genetical recombination) (JAN)
D03639  
Daclizumab (USAN/INN)
D03645  
Daniplestim (USAN/INN)
D03651  
Darbepoetin alfa (genetical recombination) (JAN)
D04032  
Epoetin delta (USAN)
D04036  
Epratuzumab (USAN/INN)
D04489  
Ibritumomab tiuxetan (genetical recombination) (JAN)
D05036  
Milodistim (USAN/INN)
D05218  
Ocrelizumab (genetical recombination) (JAN)
D05847  
Siplizumab (USAN/INN)
D06348  
Yttrium Y 90 epratuzumab (USAN)
D06349  
Yttrium Y 90 epratuzumab tetraxetan (USAN)
D06381  
Zolimomab aritox (USAN)
D06463  
Lumiliximab (USAN/INN)
D08066  
Imatinib (INN)
D08621  
Tositumomab (INN)
D08622  
Tositumomab 131 iodine
D09031  
Veltuzumab (USAN)
D09207  
Catumaxomab (INN)
D09314  
Ofatumumab (genetical recombination) (JAN)
D09321  
Obinutuzumab (USAN)
D10028  
Valategrast hydrochloride (USAN)
D10354  
Dupilumab (USAN)
D10482  
Ocaratuzumab (USAN/INN)
Organism
Homo sapiens (human) [GN:hsa]
Gene
4254  
KITLG; KIT ligand [KO:K05461]
3574  
IL7; interleukin 7 [KO:K05431]
3565  
IL4; interleukin 4 [KO:K05430]
1437  
CSF2; colony stimulating factor 2 (granulocyte-macrophage) [KO:K05427]
2323  
FLT3LG; fms-related tyrosine kinase 3 ligand [KO:K05454]
3567  
IL5; interleukin 5 [KO:K05428]
1440  
CSF3; colony stimulating factor 3 (granulocyte) [KO:K05423]
3562  
IL3; interleukin 3 [KO:K04736]
3569  
IL6; interleukin 6 [KO:K05405]
3589  
IL11; interleukin 11 [KO:K05417]
3552  
IL1A; interleukin 1, alpha [KO:K04383]
3553  
IL1B; interleukin 1, beta [KO:K04519]
7124  
TNF; tumor necrosis factor [KO:K03156]
1435  
CSF1; colony stimulating factor 1 (macrophage) [KO:K05453]
2056  
EPO; erythropoietin [KO:K05437]
7066  
THPO; thrombopoietin [KO:K06854]
947  
CD34; CD34 molecule [KO:K06474]
2322  
FLT3; fms-related tyrosine kinase 3 [KO:K05092] [EC:2.7.10.1]
1791  
DNTT; DNA nucleotidylexotransferase [KO:K00977] [EC:2.7.7.31]
960  
CD44; CD44 molecule (Indian blood group) [KO:K06256]
3815  
KIT; v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog [KO:K05091] [EC:2.7.10.1]
3559  
IL2RA; interleukin 2 receptor, alpha [KO:K05068]
3575  
IL7R; interleukin 7 receptor [KO:K05072]
7037  
TFRC; transferrin receptor [KO:K06503]
924  
CD7; CD7 molecule [KO:K06457]
914  
CD2; CD2 molecule [KO:K06449]
921  
CD5; CD5 molecule [KO:K06455]
909  
CD1A; CD1a molecule [KO:K06448]
910  
CD1B; CD1b molecule [KO:K06448]
911  
CD1C; CD1c molecule [KO:K06448]
912  
CD1D; CD1d molecule [KO:K06448]
913  
CD1E; CD1e molecule [KO:K06448]
920  
CD4; CD4 molecule [KO:K06454]
925  
CD8A; CD8a molecule [KO:K06458]
926  
CD8B; CD8b molecule [KO:K06459]
915  
CD3D; CD3d molecule, delta (CD3-TCR complex) [KO:K06450]
916  
CD3E; CD3e molecule, epsilon (CD3-TCR complex) [KO:K06451]
917  
CD3G; CD3g molecule, gamma (CD3-TCR complex) [KO:K06452]
4311  
MME; membrane metallo-endopeptidase [KO:K01389] [EC:3.4.24.11]
928  
CD9; CD9 molecule [KO:K06460]
930  
CD19; CD19 molecule [KO:K06465]
933  
CD22; CD22 molecule [KO:K06467]
CD24; CD24 molecule [KO:K06469]
931  
MS4A1; membrane-spanning 4-domains, subfamily A, member 1 [KO:K06466]
1380  
CR2; complement component (3d/Epstein Barr virus) receptor 2 [KO:K04012]
951  
CD37; CD37 molecule [KO:K06475]
2208  
FCER2; Fc fragment of IgE, low affinity II, receptor for (CD23) [KO:K06468]
1378  
CR1; complement component (3b/4b) receptor 1 (Knops blood group) [KO:K04011]
1438  
CSF2RA; colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-macrophage) [KO:K05066]
3563  
IL3RA; interleukin 3 receptor, alpha (low affinity) [KO:K04737]
945  
CD33; CD33 molecule [KO:K06473]
3566  
IL4R; interleukin 4 receptor [KO:K05071]
3570  
IL6R; interleukin 6 receptor [KO:K05055]
2209  
FCGR1A; Fc fragment of IgG, high affinity Ia, receptor (CD64) [KO:K06498]
1436  
CSF1R; colony stimulating factor 1 receptor [KO:K05090] [EC:2.7.10.1]
290  
ANPEP; alanyl (membrane) aminopeptidase [KO:K11140] [EC:3.4.11.2]
3684  
ITGAM; integrin, alpha M (complement component 3 receptor 3 subunit) [KO:K06461]
929  
CD14; CD14 molecule [KO:K04391]
3581  
IL9R; interleukin 9 receptor [KO:K05073]
3554  
IL1R1; interleukin 1 receptor, type I [KO:K04386]
7850  
IL1R2; interleukin 1 receptor, type II [KO:K04387]
1441  
CSF3R; colony stimulating factor 3 receptor (granulocyte) [KO:K05061]
3568  
IL5RA; interleukin 5 receptor, alpha [KO:K05067]
2057  
EPOR; erythropoietin receptor [KO:K05079]
948  
CD36; CD36 molecule (thrombospondin receptor) [KO:K06259]
1604  
CD55; CD55 molecule, decay accelerating factor for complement (Cromer blood group) [KO:K04006]
966  
CD59; CD59 molecule, complement regulatory protein [KO:K04008]
3590  
IL11RA; interleukin 11 receptor, alpha [KO:K05056]
3690  
ITGB3; integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) [KO:K06493]
3674  
ITGA2B; integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41) [KO:K06476]
2815  
GP9; glycoprotein IX (platelet) [KO:K06263]
2811  
GP1BA; glycoprotein Ib (platelet), alpha polypeptide [KO:K06261]
2812  
GP1BB; glycoprotein Ib (platelet), beta polypeptide [KO:K06262]
2814  
GP5; glycoprotein V (platelet) [KO:K06260]
3672  
ITGA1; integrin, alpha 1 [KO:K06480]
3673  
ITGA2; integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) [KO:K06481]
3675  
ITGA3; integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor) [KO:K06482]
3676  
ITGA4; integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor) [KO:K06483]
3678  
ITGA5; integrin, alpha 5 (fibronectin receptor, alpha polypeptide) [KO:K06484]
3655  
ITGA6; integrin, alpha 6 [KO:K06485]
2993  
GYPA; glycophorin A (MNS blood group) [KO:K06575]
3122  
HLA-DRA; major histocompatibility complex, class II, DR alpha [KO:K06752]
3123  
HLA-DRB1; major histocompatibility complex, class II, DR beta 1 [KO:K06752]
3125  
HLA-DRB3; major histocompatibility complex, class II, DR beta 3 [KO:K06752]
3126  
HLA-DRB4; major histocompatibility complex, class II, DR beta 4 [KO:K06752]
3127  
HLA-DRB5; major histocompatibility complex, class II, DR beta 5 [KO:K06752]
952  
CD38; CD38 molecule [KO:K01242] [EC:2.4.99.20 3.2.2.6]
Compound
G01078  
Lewis x-sulfated
G01493  
Lewis x-sulfated
Reference
  Authors
Janeway CA Jr, Travers P, Walport M, Shlomchik MJ
  Title
Immunobiology - International editon: The immune system in health and disease
  Journal
Harcourt Publishers Ltd, a subsidiary of Harcourt International Ltd (2001)
Reference
(Japanese)
  Authors
Abe T
  Title
[Atlas of malignancies in hematopoietic organ - Morphology, immunology, chromosome and gene] (Japanese)
  Journal
Nihonijishinhousya (2000)
Reference
  Authors
Rothenberg EV, Taghon T.
  Title
Molecular genetics of T cell development.
  Journal
Annu Rev Immunol 23:601-49 (2005)
Reference
  Authors
Ceredig R, Rolink T.
  Title
A positive look at double-negative thymocytes.
  Journal
Nat Rev Immunol 2:888-97 (2002)
Reference
  Authors
de Bruijn MF, Speck NA.
  Title
Core-binding factors in hematopoiesis and immune function.
  Journal
Oncogene 23:4238-48 (2004)
Reference
  Authors
Radtke F, Wilson A, Mancini SJ, MacDonald HR.
  Title
Notch regulation of lymphocyte development and function.
  Journal
Nat Immunol 5:247-53 (2004)
Reference
  Authors
Spits H.
  Title
Development of alphabeta T cells in the human thymus.
  Journal
Nat Rev Immunol 2:760-72 (2002)
Reference
PMID:9927518
  Authors
Di Santo JP, Aifantis I, Rosmaraki E, Garcia C, Feinberg J, Fehling HJ, Fischer A, von Boehmer H, Rocha B.
  Title
The common cytokine receptor gamma chain and the pre-T cell receptor provide independent but critically overlapping signals in early alpha/beta T cell development.
  Journal
J Exp Med 189:563-74 (1999)
Reference
  Authors
Mak TW, Penninger JM, Ohashi PS.
  Title
Knockout mice: a paradigm shift in modern immunology.
  Journal
Nat Rev Immunol 1:11-9 (2001)
Reference
  Authors
Shapiro-Shelef M, Calame K.
  Title
Regulation of plasma-cell development.
  Journal
Nat Rev Immunol 5:230-42 (2005)
Reference
  Authors
Maillard I, Adler SH, Pear WS.
  Title
Notch and the immune system.
  Journal
Immunity 19:781-91 (2003)
Reference
  Authors
Alpdogan O, van den Brink MR.
  Title
IL-7 and IL-15: therapeutic cytokines for immunodeficiency.
  Journal
Trends Immunol 26:56-64 (2005)
KO pathway
 

DBGET integrated database retrieval system